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Chemotherapy plays a major role in the treatment of patients with
gynecological malignancies. In general, chemotherapy has a smaller
therapeutic window compared with drugs of other types; hence, the
potential for severe adverse effects associated with chemotherapy has
made appropriate patient and drug selection critical.
Before initiating treatment of any patient with a chemotherapeutic
agent, the following issues should be considered:
Tumor characteristics
• The primary malignant diagnosis should be veriﬁed histologically.
• Ideally, recurrent disease should be veriﬁed by cytology or preferably
histology; it is acknowledged that this is not always possible especial-
ly in ovarian cancerwhere the diagnosis of recurrent disease is usually
based on clinical examination, determination of tumor markers,
and imaging.
• The extent of disease.
• The likelihood of tumor response (e.g. type of cancer, rate of disease
progression, interval since last treatment).
• Molecular biology if available.
• Tumor markers if appropriate.
Patient characteristics
• The patient’s age.
• The patient’s general state of health (performance status).
• Comorbidities (such as heart, liver, and kidney diseases).
• Previous cancer treatments (response and adverse effects).
• The patient’s psychosocial status.
Goals of treatment
• Cure.
• Tumor control to prolong survival.
• Palliation of symptoms.
Chemotherapy should only be given to patients with a veriﬁed
malignant disease and speciﬁed type of cancer. Ideally, the ﬁrst relapse
should be veriﬁed with cytology or histology since other primaryhttp://dx.doi.org/10.1016/j.ijgo.2015.06.011
0020-7292/© 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of
(http://creativecommons.org/licenses/by-nc-nd/4.0/).tumors may develop. Gestational trophoblastic disease is an exception
where histological conﬁrmation is not necessary prior to starting treat-
ment. Before initiation of chemotherapy the goal of treatment should be
clariﬁed. If the treatment has a curative intention (e.g. ovarian germ cell
tumors or choriocarcinoma) even substantial adverse effects are accept-
able if the probability of cure is high. When the goal of treatment is to
prolong survival, the balance of beneﬁt of treatment and adverse effects
should be carefully considered. When the goal of treatment is to reduce
the tumor burden to alleviate symptoms (palliative intention), treat-
ment should be chosen so that the probability of severe adverse effects
is small. In these cases, the patient-reported adverse effects should
not be worse than the symptoms of disease. Chemotherapeutic agents
can be used in various protocols and routes, and can be used alone or
concurrent with radiotherapy or targeted therapy.
Physicians who treat patients with chemotherapy need to have
knowledge of tumor biology, cellular kinetics, pharmacodynamics,
kinetics, and drug resistance. Tumor cells use the same pattern for
cellular division and growth as normal cells and studies indicate that
cell division does not occur more rapidly in cancer than in normal
cells. The reason for the uncontrolled cell growth seems to be due to
loss of normal cell-cycle regulation and failure of programmed cell
death (apoptosis). The time it takes for a tumor mass to double its size
is referred to as the doubling time. Animal studies indicate that tumors
grow exponentially when they are very small, but the rate of cancer
growth slows as the tumor size increases (Gompertzian growth) [1].
There is limited information concerning the doubling time in human
tumors, but in general embryonal tumors have a short doubling time
(20–40 days) while adenocarcinomas and squamous cell carcinomas
have relatively slower doubling times (50–150 days).
Chemotherapeutic agents have several mechanisms of action and
affect cancer cells in a wide variety of ways. In general, cancer cells
that are actively moving through the different phases of the cell cycle
are highly chemosensitive, while cells in a resting state (G0) are
relatively insensitive. Tumors consisting of cancer cells that are rapidly
proliferating are therefore more responsive to chemotherapy. Patients
with slowly progressive disease can live many years but, in general,
their tumors are less sensitive to chemotherapy because the majority
of tumor cells at each treatment cycle are in a resting phase. According
to the log-kill principle, chemotherapeutic agents only kill a constant
fraction of cells rather than a speciﬁc number of cells [2]. A consequence
of this hypothesis is that the chemotherapy dose should not be reduced
in the case of a small tumor burden.Gynecology and Obstetrics. This is an open access article under the CC BY-NC-ND license
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2.1. Administration of chemotherapy
Health professionals who prescribe, administer, and/or supervise
the administration of chemotherapy should be qualiﬁed to administer
chemotherapy and have acquired skills to manage its adverse effects.
The administration of chemotherapy should comply with national
requirements concerning occupational safety and health.
Chemotherapy can be dangerous to professionals, patients, and next
of kin owing to its mutagenic, teratogenic, and carcinogenic capacity.
There is also a risk of direct skin irritation or damage in case of spill.
Preparation of the drugs must be performed in areas with special
ventilation systems and only by experienced onco-pharmacists.
Appropriate clothing including special gloves and gowns should be
worn when preparing and administrating the drugs. The right concen-
tration and dilution in appropriate solutions (5% dextrose in water,
normal saline solution) and routes of administration (intravenous
push, or intravenous drip) and duration of infusion should be used.
Separate containers to dispose of the materials used when mixing
and giving the drugs are needed. The patient should be appropriately
monitored and all procedures documented in writing. At the facility
providing systemic chemotherapy medications, treatment of anaphy-
laxis should be immediately available and the staff should be trained
in cardiopulmonary resuscitation. Extravasation of a chemotherapeutic
agent acting as a vesicant (e.g. anthracyclines) can cause severe tissue
necrosis and calls for surgical intervention. Awareness of extravasation
and improved infusion techniques through a free-ﬂowing intravenous
line and careful monitoring are important preventive measures. A
clear algorithm for the use of the appropriate antidotes should be clearly
visible in the chemotherapy unit.
Adverse effects, weight, changes in performance status, and
appropriate laboratory tests should be assessed and documented before
each cycle. Quantiﬁcation of adverse effects is usually done by
employing toxicity scales such as the National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI CTCAE) [3]. Adding
patient-reported outcomemeasures (PROM)may improve the accuracy
of the assessment [4]. Patient education concerning adverse effects
and their intervention should be regarded as part of treatment. Chemo-
therapy administration safety standards have been published by the
American Society of Clinical Oncology (ASCO)/Oncology Nursing
Society [5].2.2. Minimum laboratory back-up requirements to administer chemotherapy
Immediate access to a laboratory facility is needed to receive reports
on at least a complete blood count (erythrocytes, leucocytes, platelets,
neutrophils), minimum liver function tests (alkaline phosphatase,
alanine transaminase, aspartate transaminase) and a creatinine
blood test.3. Common adverse effects and how they are managed
Chemotherapy-induced adverse effects are most commonly caused
by damage of rapidly dividing normal cells, such as bone marrow cells,
cells lining the gastrointestinal and reproductive tracts, as well as cells
of hair follicles. Most chemotherapy drugs affect all these types of
cells, but to varying degrees depending on, for example, the drug,
dose, route of administration, and patient characteristics. Genetic vari-
ants of liver enzymes involved in drug metabolism probably account
for some of the observed inter-individual differences of adverse effects,
but have yet to reach clinical application. The sequence of giving certain
chemotherapeutic agents may affect their toxicities (such as the effect
of the combination of carboplatin and paclitaxel on thrombocytopenia).3.1. Hypersensitivity reactions
Most drug reactions are mild and appear during infusion in the form
of hotﬂushes, rash, and back pain. True allergic reactions are oftenmore
severe (e.g. shortness of breath, edema, blood pressure changes) and
can even be life-threatening (anaphylaxiswith cardiovascular collapse).
Drugs that are more often associated with hypersensitivity reactions in
the treatment of gynecological malignancies are platinum, liposomal
doxorubicin, and taxanes. Despite appropriate premedication, reactions
may occur during infusion with taxanes. These reactions tend to occur
during theﬁrst cycles of treatment. Infusion reactions can oftenbe treat-
ed by stopping the infusion and restarting at a slower rate. Hypersensi-
tivity reactions associated with platinum agents occur more often
during later cycles or following re-exposure, and are more often severe.
Consider consultation with an allergist before rechallenge. Desensitiza-
tion may be considered unless life-threatening reactions have occurred.
Preparation for a possible hypersensitivity reaction should be made
each time a patient is infused with chemotherapy. More speciﬁc guide-
lines are readily assessable, for example, the National Comprehensive
Cancer Network guidelines (www.nccn.org).
3.2. Bone marrow/blood cells
The bone marrow is the most common site for chemotherapy-
induced adverse effects. Neutropenia usually occurs 7–10 days after
treatment and during these periods there is an increased risk for infec-
tious complications. The incidence of febrile neutropenia is relatively
low when using standard chemotherapy for gynecologic malignancies.
In general, there is no indication for the prophylactic use of granulocyte
colony-stimulating factors (G-CSFs). In case of treatment delays due to
neutropenia, the appropriate management should take the goal of the
treatment into account. To keep the course interval intact, dose reduc-
tion and/or the use of prophylactic G-CSFsmay be appropriate. Interna-
tional guidelines for G-CSF administration are readily available [6,7].
The use of erythropoiesis-stimulating agents (ESAs) to treat
chemotherapy-induced anemia is debatable because of an increased
risk of thromboembolic events and the association with shorter surviv-
al. However, the mechanism behind the observed association between
ESAs and shorter survival in cancer patients is unclear. It is also
unknownwhether all patients are at risk for being harmed. ASCO guide-
lines recommend that ESAs may be a treatment option for patients
undergoing myelosuppressive chemotherapy who have hemoglobin
levels less than 10 g/dL [8]. However, the potential harms and beneﬁts
of ESAs (e.g. decreased transfusions) need to be carefully discussed
with the patient, and compared with the potential harms (e.g. infec-
tions, immune-mediated adverse reactions) and beneﬁts (e.g. rapid
hemoglobin improvement) of blood transfusions.
The onset and recovery of thrombocytopenia is slightly later
comparedwith neutropenia. The sequence of giving certain chemother-
apeutic agents may affect their toxicities (such as the effect of the
combination of carboplatin and paclitaxel on thrombocytopenia).
There is an increased risk of hemorrhagic complications when platelet
counts drop to less than 50 000/mm3 and there is a particularly
high risk of spontaneous bleeding once the platelet count is less than
10 000/mm3. Thrombocytopenia can be a challenging clinical problem
to treat. Platelet transfusions can provide temporary relief, but often
thrombocytopenia involves dose reductions or treatment delays.
3.3. Nausea and vomiting
Patients rate nausea/vomiting as one of the most distressing
adverse effects following chemotherapy. The incidence and severity of
chemotherapy-induced nausea/vomiting are affected by several factors,
including the speciﬁc chemotherapeutic agents used, as well as dosage,
schedule, and route of administration. The risk is increased among
women and patient-related factors such as age under 50 years; previous
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chemotherapy emesis or anesthesia emesis; and anxiety. Alcoholism
decreases the risk of emesis. Chemotherapy-induced nausea/vomiting
is classiﬁed as acute or delayed. Acute-onset emesis usually occurs
within a few minutes to several hours and commonly resolves within
the ﬁrst 24 hours after drug administration. Delayed-onset emesis
develops more than 24 hours after chemotherapy administration and
generally peaks 48–72 hours after administration. Depending on the
speciﬁc chemotherapy used, it can last for up to 7 days.
The goal of antiemetic therapy is to prevent nausea/vomiting;
therefore, antiemetic therapy should be initiated before chemotherapy
administration. The choice of antiemetic used is based on the emeto-
genic potential of the chemotherapy, prior experience with antie-
metics, and patient risk factors. The emetogenicity of chemotherapy is
classiﬁed in four categories according to the percentage of patients not
receiving antiemetic prophylaxis who experience acute emesis: highly
emetogenic agents (≥90% risk of acute emesis);moderately emetogenic
agents (30%–90% risk); low emetogenic agents (10%–30% risk); and
minimal emetogenic agents (b10% risk). ASCO guidelines for the use
of antiemetics have recently been updated [9]. The key recommenda-
tion for patients receiving highly emetic chemotherapy regimens
is a 3-drug combination of neurokinin 1 (NK1) antagonist, serotonin
5-HT3 receptor antagonist, and dexamethasone. For moderate emetic
regimens, the recommendation is a 2-drug combination of palonosetron
and a corticosteroid. If palonosetron is not available, it may be substitut-
ed by a ﬁrst-generation 5-HT3 antagonist. A single 8-mg dose of
dexamethasone before chemotherapy is suggested for low emetogenic
chemotherapy agents and no routine prophylactic antiemetics are
recommended for minimal emetogenic agents. For patients receiving
combination chemotherapy, antiemetic treatment is chosen according
to the agentwith the highest degree of emetic risk. Oral and intravenous
5-HT3 antagonists have equivalent efﬁcacy when used at appropriate
doses. For selected patients unable to swallow, the transdermal route
may be of value. For patients with anticipatory emesis (occurring before
the patient receives chemotherapy), the most active antiemetic
regimens appropriate for the chemotherapy used should be chosen
initially. If anticipatory emesis occurs, behavioral therapy is suggested.
The incidence of anticipatory emesis varies between 18% and 57%, and
nausea is more common than vomiting.
Acupuncture point stimulation may be of some beneﬁt [10],
especially if modern antiemetic drugs are not available. In addition,
adjustment of eating habits, such as small frequent meals, may alleviate
nausea/vomiting. Other potential causes of emesis also need to be
considered, such as bowel obstruction, dyspepsia, brain metastasis,
electrolyte imbalance, and uremia.
Patients treatedwith chemotherapymay experienceweight loss due
to loss of appetite, changes to sense of taste (e.g. metallic), sore mouth,
diarrhea, and constipation. Contributing factorsmay bepain, psycholog-
ical factors, and poor performance status. Weight should be monitored
before each chemotherapy cycle. In case of weight loss exceeding
more than 10% for adults, appropriate investigation and directed thera-
py should be initiated and a dietary consultation is recommended.
3.4. Alopecia
Hair loss, or the fear of it, is one of the most troublesome adverse
effects of chemotherapy. Many chemotherapy agents do not induce
complete hair loss, but make the hair thin, fragile, and easily broken.
The effects usually begin within 2–3 weeks after initial chemotherapy,
but for taxanes, which often lead to complete alopecia, onset is quicker.
Hair grows back after treatment in almost all cases, and a full head is
seen after 3–6 months. During regrowth, the hair may have altered
color and structure. Proper pretreatment information about the risk of
hair loss, prescription of wigs when appropriate, and tips for headwear
and creation of new eyebrows and lashes may be helpful and provide
a feeling of control. There is some evidence that scalp cooling canreduce hair loss during treatment with some chemotherapy agents
[11]. However, it should not be used if there is a high risk of cancer
cells surviving in the blood vessels of the scalp, such as certain hemato-
logical malignancies.
3.5. Peripheral neuropathy
Chemotherapy-induced peripheral neuropathy is a major dose-
limiting adverse effect of chemotherapy drugs commonly used in
gynecological malignancies, such as platinum and taxane. Peripheral
neuropathy typically occurs in 30%–40% of patients and can begin
during or after the end of treatment. The symptoms, including pain,
numbness/tingling, sensory loss, and functional impairment, are often
only partially reversible and the neuronal damage can be permanent.
The risk of peripheral neuropathy is related to the chemotherapeutic
drug, cumulative dose, and the concomitant use of several neurotoxic
agents. The risk is also associated with patient characteristics such
as age and pre-existing neuropathy (e.g. alcohol, diabetes induced,
vitamin B12 deﬁciency, and hypothyroidism). There is currently no
evidence-based pharmacological agent that can efﬁciently prevent or
treat chemotherapy-induced peripheral neuropathy [12]. Therefore,
early detection of symptoms before they interfere with function and
activities of daily life is the best way to prevent the condition becoming
disabling. Dose modiﬁcation, changing paclitaxel to, for example,
docetaxel, or even withdrawal of taxane may be necessary in plati-
num–taxane combination therapy. Patient needs include appropriate
shoes and awareness of potential hand and foot injuries due to
reduced neurosensitivity.
3.6. Sexual dysfunction, reproduction, and pregnancy
Sexual dysfunction is a common and distressing problem among
women treated for gynecological malignancies. The reason is multifac-
torial and includes decreased interest in sex and physical problems
such as dyspareunia and vaginal dryness. Although treatment-induced
sexual dysfunction is caused mainly by previous surgery and/or radio-
therapy, chemotherapy can affect the vaginalmucosa leading to dryness
and superﬁcial bleeding. In addition, vaginal infections such as fungus or
herpes may be reactivated. Sexual dysfunction needs to be actively
addressed and management may include lubricants, hormone replace-
ment therapy, vaginal dilatators, and sexual counseling when appropri-
ate. Patient education is important and should include information that
there is nomedical reason for not engaging in sexual activity during the
chemotherapy treatment period.
The risk of chemotherapy-induced permanent ovarian insufﬁciency
and infertility depends on patient age, drug dose, and speciﬁc
chemotherapeutic agent. The risk increases from 30 years of age and is
pronounced among women older than 40 years, especially after treat-
ment with alkylating agents. Women younger than 30 years who
receive platinum-based chemotherapy will often have temporary
amenorrhea, but ovarian function commonly recovers. It is important
that patients use effective contraception during and up to one year
after completion of chemotherapy. Women who have not completed
childbearing and are at risk of infertility should discuss germ cell
preservation options with the medical team. The research ﬁeld within
female fertility preservation is rapidly changing, and no longer results
in a signiﬁcant delay in the initiation of cancer treatment.
Chemotherapy has potential mutagenic, teratogenic, and carcino-
genic effects for the embryo depending on chemotherapy agent, dose,
and gestational stage. Gynecologic cancer during pregnancy is challeng-
ing and should bemanaged by amultidisciplinary team. Both themater-
nal prognosis and the risk for the fetus need to be taken into account.
Chemotherapy should be avoided during the ﬁrst trimester of gestation
but selective agents can be administered with reasonable safety during
the second and third trimester without an excessive increased risk for
the fetus [13,14]. A three-week period should be allowed between the
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should be postponed preferably until 37 weeks or more of pregnancy.
However, long-term follow-up is limited andprospective studies are lack-
ing. Breastfeeding should be avoided during chemotherapy treatment.
3.7. Other adverse effects
Some of the chemotherapy agents that are used to treat gynecolog-
ical malignancies are recognized for their potential nephrotoxic effects.
These are cisplatin, ifosfamide, cyclophosphamide, and methotrexate.
Renal function should be monitored before every cycle and adequate
hydration given before and after treatment to maintain adequate
diuresis. Mannitol should be administered if indicated. Cognitive
impairment and fatigue are other more general adverse effects that
can affect women during and after chemotherapy.
Healthcare professionals should be educated and trained in
assessing and managing adverse effects. Patient and next of kin educa-
tion about the acute and late adverse effects of chemotherapy should
be an integral part of cancer treatment. Cancer rehabilitation should
start at cancer diagnosis.
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